Search clinical trials for: HIV seronegativity

Total 12837 results

Centre Hospitalier Annecy Genevois

Completed

Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region (PrEP2A)

HIV Seronegativity | Pre-Exposure Prophylaxis | Drug Combination

France
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
University of California, Los Angeles
National Institute of Mental Health (NIMH)

Completed

Support To Reunite Involve and Value Each Other (STRIVE)

Substance Use | Family Relations | Risky Sexual Behavior | Runaway Behavior
National Institute of Allergy and Infectious Diseases...
National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaborators

Completed

Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding

HIV Infections

Zimbabwe, South Africa, Tanzania, Uganda
National Institute of Allergy and Infectious Diseases...
Microbicide Trials Network

Completed

Bone Mineral Density Substudy - An Ancillary Study to MTN-003

HIV Infections

Zimbabwe, Uganda
Fenway Community Health
Merck Sharp & Dohme LLC

Completed

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

HIV Infections

United States
HIV Prevention Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Women's HIV SeroIncidence Study (ISIS)

HIV Infections

United States
HIV Prevention Trials Network
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

HIV Incidence and Participation Retention in Pune, India

HIV Infections | HIV Seronegativity

India
HIV Prevention Trials Network
National Institute on Drug Abuse (NIDA); National Institute of Allergy and... and other collaborators

Completed

Feasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

HIV Infections

United States, Peru
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

HIV Infections

United States
Centers for Disease Control and Prevention
Botswana Ministry of Health

Completed

Open Label Extension (OLE) of the TDF2 Study, Botswana (TDF2-OLE)

HIV Infections
National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
National Institute of Allergy and Infectious Diseases...
National Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaborators

Completed

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

HIV Infections

United States, Malawi, South Africa, Zambia, Zimbabwe
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

HIV Infections

Thailand
National Institute of Allergy and Infectious Diseases...
National Institute on Drug Abuse (NIDA)

Terminated

Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

HIV Infections | Opioid-Related Disorders

China, Thailand
National Institute of Allergy and Infectious Diseases...
HIV Prevention Trials Network

Completed

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

HIV Infections

Brazil, Malawi, India, Botswana, Kenya, South Africa, Zimbabwe, United States, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Pasteur Merieux Connaught

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Genentech, Inc.; Biocine

Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

HIV Infections | HIV Seronegativity

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Protein Sciences Corporation

Completed

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Immuno-US

Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Bill and Melinda Gates Foundation

Completed

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men (iPrEx)

HIV Infections

United States, Brazil, Ecuador, Peru, South Africa, Thailand
National Institute of Allergy and Infectious Diseases...
Harvard School of Public Health (HSPH)

Completed

Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV

HIV Infections

Botswana
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Biocine

Completed

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59

HIV Infections | HIV Seronegativity

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)

HIV Infections

United States

3

Subscribe